Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: Findings from the etanercept PRESTA trial

Clinical and Experimental Rheumatology

Volumn 33, Issue 1, 2015, Pages 11-19

  Kirkham, Bruce ^a   de Vlam, Kurt ^b   Li, Wenzhi ^c   Boggs, Robert ^d   Mallbris, Lotus ^d   Nab, Henk W ^d   Tarallo, Miriam ^d  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c IQVIA   (United States)

^d PFIZER INC   (United States)

Author keywords

Disease duration; Etanercept; Psoriatic arthritis

Indexed keywords

ETANERCEPT; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN G; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTHRALGIA; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSESSMENT; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; EARLY INTERVENTION; EURO QOL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PHYSICIAN GLOBAL ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SWOLLEN JOINT COUNT; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE; ARTHRITIS, PSORIATIC; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; HEALTH STATUS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PSYCHOLOGY; REMISSION; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME; TIME TO TREATMENT;

ADULT; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, PSORIATIC; CHI-SQUARE DISTRIBUTION; FEMALE; HEALTH STATUS; HUMANS; IMMUNOGLOBULIN G; LINEAR MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TIME-TO-TREATMENT; TREATMENT OUTCOME;

EID: 84928697667     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. GLADMAN DD: Psoriatic arthritis. Dermatol Ther 2004; 17: 350-63.
2. GLADMAN DD, STAFFORD-BRADY F, CHANG CH, LEWANDOWSKI K, RUSSELL ML: Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990; 17: 809-12.
3. SOKOLL KB, HELLIWELL PS: Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001; 28: 1842-6.
4. RAHMAN P, NGUYEN E, CHEUNG C, SCHEN-TAG CT, GLADMAN DD: Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol 2001; 28: 1041-4.
5. SAAD AA, SYMMONS DP, NOYCE PR, ASHCROFT DM: Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008; 35: 883-90.
6. ROSEN CF, MUSSANI F, CHANDRAN V, EDER L, THAVANESWARAN A, GLADMAN DD: Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford) 2012; 51: 571-6.
7. MEASE P, GOFFE BS: Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005; 52: 1-19.
8. GLADMAN DD, SHUCKETT R, RUSSELL ML, THORNE JC, SCHACHTER RK: Psoriatic arthritis (PSA)-an analysis of 220 patients. Q J Med 1987; 62: 127-41.
9. SCARPA R, COSENTINI E, MANGUSO F et al.: Clinical and genetic aspects of psoriatic arthritis "sine psoriasis". J Rheumatol 2003; 30: 2638-40.
10. CONAGHAN PG, COATES LC: Improving recognition of psoriatic arthritis. Practitioner 2009; 253: 15-8, 2-3.
11. OLIVIERI I, D'ANGELO S, PADULA A, PALAZZI C: The challenge of early diagnosis of psoriatic arthritis. J Rheumatol 2008; 35: 3-5.
12. RITCHLIN CT, KAVANAUGH A, GLADMAN DD et al.: Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-94.
13. NASH P, CLEGG DO: Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005; 64 (Suppl. 2): ii74-7.
14. ETTEHADI P, GREAVES MW, WALLACH D, ADERKA D, CAMP RD: Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-51.
15. PARTSCH G, STEINER G, LEEB BF, DUNKY A, BROLL H, SMOLEN JS: Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24: 518-23.
16. ANTONI C, KRUEGER GG, de VLAM K et al.: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64: 1150-7.
17. MEASE PJ, KIVITZ AJ, BURCH FX et al.: Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006; 33: 712-21.
18. MEASE PJ, ORY P, SHARP JT et al.: Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009; 68: 702-9.
19. MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90.
20. GENOVESE MC, BATHON JM, MARTIN RW et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-50.
21. KANE D, STAFFORD L, BRESNIHAN B, FITZ-GERALD O: A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003; 42: 1460-8.
22. GLADMAN DD, FAREWELL VT: Progression in psoriatic arthritis: role of time varying clinical indicators. J Rheumatol 1999; 26: 2409-13.
23. SCARPA R, CUOCOLO A, PELUSO R et al.: Early psoriatic arthritis: the clinical spectrum. J Rheumatol 2008; 35: 137-41.
24. SCARPA R, ATTENO M, LUBRANO E et al.: The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin Rheumatol 2011; 30: 1063-7.
25. OLIVIERI I, D'ANGELO S, PALAZZI C, PADULA A: Treatment strategies for early psoriatic arthritis. Expert Opin Pharmacother 2009; 10: 271-82.
26. KANE D, PATHARE S: Early psoriatic arthritis. Rheum Dis Clin North Am 2005; 31: 641-57.
27. STERRY W, ORTONNE JP, KIRKHAM B et al.: Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010; 340: c147.
28. GNIADECKI R, ROBERTSON D, MOLTA CT et al.: Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. J Eur Acad Dermatol Venereol 2012; 26: 1436-43.
29. PRINZ JC, FITZGERALD O, BOGGS RI et al.: Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial. J Eur Acad Dermatol Venereol 2010; 25: 559-64.
30. ASHCROFT DM, WAN PO AL, WILLIAMS HC, GRIFFITHS CE: Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999; 141: 185-91.
31. FREDRIKSSON T, PETTERSSON U: Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
32. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
33. COATES LC, FRANSEN J, HELLIWELL PS: Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010; 69: 48-53.
34. THE EUROQOL GROUP: EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16: 199-208.
35. BRUCE B, FRIES JF: The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003; 30: 167-78.
36. FRIES JF, SPITZ P, KRAINES RG, HOLMAN HR: Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
37. ZIGMOND AS, SNAITH RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
38. ALETAHA D, SMOLEN J, WARD MM: Meas-uring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum 2006; 54: 2784-92.
39. ALETAHA D, STRAND V, SMOLEN JS, WARD MM: Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis 2008; 67: 238-43.
40. GLADMAN DD, THAVANESWARAN A, CHANDRAN V, COOK RJ: Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?. Ann Rheum Dis 2011; 70: 2152-4.
41. YAZICI Y: Treat-to-target: measures. Clin Exp Rheumatol 2012; 30: S7-9.
42. SMOLEN JS: Treat-to-target: rationale and strategies. Clin Exp Rheumatol 2012; 30 (Suppl. 73): S2-6.
43. CASTREJON I, PINCUS T: Patient self-report outcomes to guide a treat-to-target strategy in clinical trials and usual clinical care of rheumatoid arthritis. Clin Exp Rheumatol 2012; 30: S50-5.
44. KAVANAUGH A: Psoriatic arthritis: treat-to-target. Clin Exp Rheumatol 2012; 30 (Suppl. 73): S123-5.
45. O'BRIEN BJ, DRUMMOND MF: Statistical versus quantitative significance in the socioeconomic evaluation of medicines. Pharmacoeconomics 1994; 5: 389-98.
46. SHIKIAR R, WILLIAN MK, OKUN MM, THOMPSON CS, REVICKI DA: The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006; 4: 71.
47. MEASE PJ, GANGULY R, WANKE L, YU E, SINGH A: How much improvement in functional status is considered important by patients with active psoriatic arthritis: Applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Ann Rheum Dis 2004; 63: 391-92.
48. MEASE PJ, WOOLLEY JM, BITMAN B, WANG BC, GLOBE DR, SINGH A: Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol 2011; 38: 2461-5.